Fosaprepitant

DRUG20 trials

Sponsors

Region Vaesternorrland, Umea University, Gynecologic Oncology Associates, M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC, Lawrence Einhorn

Conditions

Adverse Effects of Medical DrugsAntiemeticBreast CancerCINVCervical CancerChemotherapy Induced Nausea and VomitingChemotherapy Induced Nausea and Vomiting Pediatric Cancer PatientsChemotherapy-Induced Nausea and Vomiting

Early Phase 1

Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury

WithdrawnNCT03035838

Arun GuptaTraumatic Brain Injury

Start: 2021-11-30End: 2023-04-30Updated: 2022-11-03

Phase 1

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

CompletedNCT02780609

H. Lee Moffitt Cancer Center and Research InstituteMultiple Myeloma

Start: 2017-07-20End: 2021-02-23Updated: 2022-11-04

Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

CompletedNCT04636632

Sun Yat-sen UniversityNasopharyngeal Carcinoma

Start: 2020-11-24End: 2022-11-04Updated: 2022-11-07

Phase 2

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

CompletedNCT01697579

Merck Sharp & Dohme LLCChemotherapy-induced Nausea and Vomiting

Start: 2012-12-13End: 2016-11-21Updated: 2019-06-25

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

CompletedNCT01736917

Lawrence EinhornChemotherapy-Induced Nausea and Vomiting

Start: 2013-01-31End: 2015-06-30Updated: 2016-05-25

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

CompletedNCT01857232

Acacia Pharma LtdCINV

Start: 2013-10-31End: 2015-02-28Updated: 2020-11-25

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

TerminatedNCT01874119

St. Louis UniversityChemotherapy-induced Nausea and Vomiting

Start: 2013-09-30End: 2015-12-03Updated: 2018-06-07

Phase 3

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

CompletedNCT02106494

Heron TherapeuticsChemotherapy-induced Nausea and Vomiting

Start: 2014-03-01End: 2015-05-01Updated: 2026-03-02

Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

TerminatedNCT02519842

Merck Sharp & Dohme LLCChemotherapy-induced Nausea and Vomiting

Start: 2015-09-14End: 2017-02-24Updated: 2019-03-15

Granisetron Transdermal Patch for Prophylaxis of Delayed CINV

Fudan UniversityChemotherapy-induced Nausea and Vomiting (CINV)

Start: 2021-06-10End: 2023-12-30Target: 140Updated: 2021-06-03

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

CompletedNCT05564286

Shantou University Medical CollegeAntiemetic, Cervical Cancer, Chemotherapy-induced Nausea and Vomiting +2

Start: 2021-07-01End: 2023-08-30Updated: 2024-02-06

Postoperative recovery with the addition of long-acting NK1- and 5-HT3 receptor antagonists as prophylaxis for post-operative nausea and vomiting. A prospective, double-blind, randomized trial in laparoscopic surgery.

Not yet recruitingCTIS2025-522529-36-00

Region Vaesternorrland, Umea UniversityPost-operative nausea and vomiting (PONV)

Target: 220Updated: 2025-12-15

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

RecruitingNCT07413809

The Affiliated People's Hospital of Ningbo UniversityMultiple Myeloma

Start: 2025-10-31End: 2027-09-01Target: 92Updated: 2026-02-17

Phase 4

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

CompletedNCT01432015

Gynecologic Oncology AssociatesOvarian Cancer, Uterine Cancer

Start: 2011-09-30End: 2015-03-31Updated: 2017-03-28

PALONOSETRON X FOSAPREPITANT IN PONV

Hospital Federal de BonsucessoNausea and Vomiting, Postoperative

Start: 2019-03-02End: 2020-12-01Target: 100Updated: 2019-03-12

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Not yet recruitingNCT05841849

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityBreast Cancer, Chemotherapy-induced Nausea and Vomiting

Start: 2023-07-31End: 2029-07-31Target: 1028Updated: 2023-05-03

Unknown Phase

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

CompletedNCT01490060

M.D. Anderson Cancer CenterAdverse Effects of Medical Drugs, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy +1

Start: 2012-05-31End: 2016-03-31Updated: 2016-04-11

Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients

Shanghai Children's Medical CenterChemotherapy Induced Nausea and Vomiting, Pediatric Cancer Patients

Start: 2021-05-01End: 2021-12-30Target: 120Updated: 2021-05-10

Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs

Shanghai Children's Medical CenterChemotherapy Induced Nausea and Vomiting Pediatric Cancer Patients

Start: 2022-02-01End: 2022-05-01Target: 120Updated: 2022-02-09

Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention

Enrolling by invitationNCT05773950

Samsung Medical CenterGynecologic Surgical Procedures, Laparoscopy, Postoperative Nausea and Vomiting

Start: 2023-08-18End: 2025-12-31Target: 144Updated: 2025-03-30

Related Papers

Granisetron Transdermal Delivery System Versus Palonosetron in the Prevention of Long-delayed Nausea and Vomiting: A Phase III Randomized Trial.

2026-01-10

Comparison of oral aprepitant and intravenous fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric oncology patients: a randomized phase III trial

Translational Pediatrics2024-01-011 citations

Efficacy of fosaprepitant combined with tropisetron plus dexamethasone in preventing nausea and emesis during fractionated radiotherapy with weekly cisplatin chemotherapy: interim analysis of a randomized, prospective, clinical trial using competing risk analysis.

2023-10-18

Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy–Induced Nausea and Vomiting

JAMA Network Open2023-07-272 citations

Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma

Cancer Research2020-10-0618 citations

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Blood2019-11-1310 citations

Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.

2018-11-2811 citations

Pharmacokinetics/pharmacodynamics (PK/PD), safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric subjects.

Journal of Clinical Oncology2017-11-01

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Blood2016-12-025 citations

Effect of APF530 on health-related quality of life (QOL) and other chemotherapy-induced nausea and vomiting (CINV) end points: Phase III MAGIC trial.

Journal of Clinical Oncology2016-05-203 citations

Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender.

Journal of Clinical Oncology2016-05-201 citations

APF530 (Granisetron Injection Extended-Release) in a Three-Drug Regimen for Delayed CINV in Highly Emetogenic Chemotherapy

Future Oncology2016-03-2122 citations

Abstract P1-10-07: Phase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended 3-drug regimen for prevention of chemotherapy-induced nausea and vomiting due to anthracycline + cyclophosphamide (AC)–based highly emetogenic chemotherapy (HEC) regimens: A post hoc subgroup analysis of the MAGIC trial

Cancer Research2016-02-152 citations

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study

Supportive Care in Cancer2016-02-0210 citations

Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist + corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial.

Journal of Clinical Oncology2015-10-01

Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: A Hoosier Cancer Research Network Study.

Journal of Clinical Oncology2015-05-202 citations

Effects of fosaprepitan (Fosa) on ifosfamide (Ifex) metabolism in sarcoma patients (pts) receiving multi-day chemotherapy (CT) regimen on doxorubicin (Dox) and Ifex (AI): Randomized, cross-over study.

Journal of Clinical Oncology2015-05-20

Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receiving multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosafamide (AI): Randomized cross-over study.

Journal of Clinical Oncology2014-05-203 citations

Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153.

Journal of Clinical Oncology2014-05-202 citations